A step in the right direction

Journal of Clinical Oncology

Volumn 24, Issue 23, 2006, Pages 3717-3718

  Swain, Sandra M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB; TUMOR PROTEIN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; EDITORIAL; GENE EXPRESSION PROFILING; HUMAN; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TREATMENT RESPONSE; BREAST TUMOR; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; GENE EXPRESSION REGULATION; INCIDENCE; LYMPH NODE METASTASIS; METABOLISM; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 33747329105     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.7025     Document Type: Editorial

References (23)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. National Cancer Institute DCCPS SRP, Cancer Statistics Branch: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), 2006
3. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
4. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
5. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
6. Lippman ME, Allegra JC, Thompson EB, et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
7. Early Breast Cancer Trialists' Collaborative Group (EBCTG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
8. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and Outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
9. Wells CA, Sloane JP, Coleman D, et al: Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union: An inter-laboratory study. Virchows Arch 445:119-128, 2004
10. Schnitt SJ: Estrogen receptor testing of breast cancer in current clinical practice: What's the question? J Clin Oncol 24:1797-1799, 2006
11. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor- positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
12. Fisher B, Jeong JH, Bryant J, et al: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858-868, 2004
13. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology. http://nccn.org/professionals/physician_gls/PDF/breast.pdf
14. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
15. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
16. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
17. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
18. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
19. Wang Y, Klijn JGM, Zhang Y, et al: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679, 2005
20. Chang HY, Nuyten DS, Sneddon JB, et al: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102:3738-3743, 2005
21. Oh DS, Troester MA, Usary J, et al: Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 24:1656-1664, 2006
22. Sprarano J, Hayes D, Dees E, et al: Phase III randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with various levels of risk for recurrence. http://www.cancer.gov/ clinicaltrials/ECOG-PACCT-1
23. MINDACT Design and MINDACT trial overview. http://www. breastinternationalgroup.org/transbig.html